Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Inclusion Criteria: * Histologically proven metastatic oesophageal squamous cell carcinoma * Patient in failure with 1st-line treatment with oxaliplatin or cisplatin. Patients presenting with resectable disease treated with surgery or neoadjuvant or adjuvant chemotherapy with oxaliplatin or cisplatin (with or without radiotherapy) can be included if a recurrence has occurred less than 6 months after the end of treatment * Age ≥ 18 years * Unresectable disease, measurable or not, according to RECIST 1.1 criteria * WHO performance status ≤ 2 * Neutrophils ≥ 1500/mm3 (without use of haematopoietic growth factors), platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dl (blood transfusions are authorised for patients with a haemoglobin less than 9 g/dl) * Total bilirubin ≤ 2 x ULN (biliary drainage is authorised in case of a biliary obstruction); albumin ≥ 25 g/L; AST ≤ 2.5 x ULN, and ALT ≤ 2.5 x ULN (≤ 5 x ULN in case of hepatic metastases) * Creatinine clearance ≥ 50 ml/min according to MDRD formula * A normal ECG or ECG with no clinically significant findings * Patient able to understand and to sign the informed consent form (or who has a legal guardian able to do so for him/him) * Women of childbearing potential must have a negative pregnancy blood or urine test within 7 days prior to inclusion * Women of childbearing potential, as well as men (who have sexual relations with women of childbearing potential) must agree to use an effective method of contraception throughout this study a…